Conatus Pharmaceuticals (CNAT) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Brean Capital Cuts Price Target on Conatus Pharmaceuticals (CNAT) to $7; Reiterates Buy
May 9, 2016 9:58 AM EDTBrean Capital maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), and cut the price target to $7.00 (from $13.00), following the company's 1Q earnings report. CNAT reported EPS of ($0.35), compared to the consensus estimate of ($0.34). However, Brean Capital believes that the financial results are immaterial at this time. Management provided details on Conatus, which has 2 ongoing Phase II clinical... More
